



FOR IMMEDIATE RELEASE

IMMUNOTEC ANNOUNCES NEW CEO

VAUDREUIL-DORION, QC, May 17, 2013 - Immunotec Inc. (TSX Venture Exchange: IMM), a Canadian based company and a leader in the wellness industry ("Immunotec" or the "Company"), today announced the appointment of Mr. Charles L. Orr as its Chief Executive Officer.

Mr. Orr has served since March 2009 as Executive Director of the Direct Selling Education Foundation, where he held ultimate responsibility for the Foundation's programs and activities. Since 2001, he has provided his proven and successful expertise by active participation as a board member and advisor in a variety of publicly traded and privately held organizations ranging from over a billion dollars in revenue to start-ups. Mr. Orr served as President and Chief Executive Officer of Shaklee Corporation (1993-2000), where he was responsible for the performance of the company's diverse business units. Shaklee, then a \$700m revenue company, included the brand names of Harry and David, Jackson and Perkins, and Shaklee. Mr. Orr has been a director of Immunotec since 2006.

Mr. Orr is a seasoned professional with 23 years of experience in the direct selling field. Additionally, his work history includes extensive leadership responsibility in the financial services and computer industries. Mr. Orr was selected as Chief Executive Officer based on a track record leading complex organizations, as well as strong executive and personal qualities. Mr. Orr earned a BA in Psychology from Wesleyan University and an MBA from the University of Connecticut.

In 2005, Mr. Orr received the distinctive Circle of Honor Award from the Direct Selling Education Foundation. In 2007, he was honored by the Direct Selling Association with its prestigious Hall of Fame Award.

Mr. Orr will work out of the Corporation's offices in Vaudreuil, Quebec once all immigration approvals have been obtained.

About Immunotec Inc.

Immunotec is a world class business opportunity supported by unique scientifically proven products that improve wellness. Headquartered with manufacturing facilities near Montreal, Canada, the Company also has distribution capacities to support its commercial activities in Canada and internationally to the United States, Europe, Mexico and the Caribbean.

The Company files its consolidated financial statements, its management and discussion analysis report, its press releases and such other required documents on the SEDAR database at www.sedar.com and on the Company's website at www.immunotec.com. The common shares of the Company are listed on the TSX Venture Exchange under the ticker symbol IMM.



Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information: Charles Orr, Immunotec Inc., (450) 510-4463.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS: Certain statements contained in this news release are forward-looking and are subject to numerous risks and uncertainties, known and unknown. For information identifying known risks and uncertainties and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the heading Risks and Uncertainties in Immunotec's most recent Management's Discussion and Analysis, which can be found at www.sedar.com. Consequently, actual results may differ materially from the anticipated results expressed in these forward-looking statements.